Pacific Biosciences of California Inc

12 de nov. de 2026, 21:01 UTC

Pacific Biosciences of California, Inc. shares fell sharply, extending a downward trend with cumulative returns down significantly since Wednesday's close.

11 de nov. de 2026, 23:01 UTC

Pacific Biosciences of California, Inc. is trading higher in after-market hours, maintaining a cumulative return since Wednesday's close amid a broader market rise.

10 de nov. de 2026, 22:01 UTC

Pacific Biosciences announces a sales agreement with Allen & Co. for up to $100 million in common stock through an at-the-market equity offering program.

9 de nov. de 2026, 21:03 UTC

Pacific Biosciences is advancing sharply, reaching its highest cumulative return since Friday, despite initial volatility earlier in the session.

7 de nov. de 2026, 00:01 UTC

Pacific Biosciences of California, Inc. shares are trading modestly lower in after-market hours, continuing a trend of lower closes over the past three sessions.

6 de nov. de 2026, 23:41 UTC

Pacific Biosciences of California, Inc. is trading modestly lower in after-market hours, marking its fourth consecutive session of declines.

5 de nov. de 2026, 23:36 UTC

ARK Genomic Revolution ETF declined in after-market trading as several holdings reported larger-than-expected net losses, with Pacific Biosciences also falling modestly.

4 de nov. de 2026, 23:31 UTC

Pacific Biosciences reports Q3 revenue of $40.6 million, exceeding expectations, and narrows 2026 revenue guidance to $155 million to $160 million.

3 de nov. de 2026, 23:41 UTC

Pacific Biosciences is advancing in after-market trading, supported by positive economic indicators and a broadly higher market, despite mixed earnings from Apple.

2 de nov. de 2026, 23:11 UTC

Pacific Biosciences of California, Inc. is seeing notable strength in after-market trading, recovering from a low point shortly after the market closed.

31 de out. de 2026, 00:01 UTC

In after-market trading, Pacific Biosciences of California, Inc. has advanced sharply since Friday's close, remaining well above its 20-day moving average.

30 de out. de 2026, 23:41 UTC

Pacific Biosciences is advancing in after-market trading, reaching a high that significantly exceeds Friday's close and is well above its 20-day moving average.

29 de out. de 2026, 23:01 UTC

Pacific Biosciences of California, Inc. is trading lower in after-market hours, reflecting a broader market decline influenced by disappointing earnings from Illumina.

28 de out. de 2026, 23:02 UTC

Pacific Biosciences of California, Inc. is trading lower in after-market hours, reflecting the broader market's decline following the Fed's interest rate decision.

27 de out. de 2026, 23:06 UTC

Pacific Biosciences of California, Inc. is trading modestly lower in after-market hours, continuing a downward trend despite strong performance over the past month.

26 de out. de 2026, 23:06 UTC

Pacific Biosciences of California Inc is trading lower in after-market hours, retracing from an earlier gain, despite a strong one-month performance.

23 de out. de 2026, 19:16 UTC

Pacific Biosciences of California Inc is trading roughly flat, showing little change since Thursday's close, while remaining below its 20-day moving average.

22 de out. de 2026, 19:56 UTC

Pacific Biosciences of California Inc shares fell, influenced by declines in the ARK Genomic Revolution ETF and its holdings, including 10X Genomics and Illumina.

21 de out. de 2026, 23:16 UTC

Pacific Biosciences of California Inc is trading modestly higher in after-market hours, marking its fifth consecutive session of gains.

20 de out. de 2026, 23:16 UTC

Pacific Biosciences of California Inc is trading modestly higher in after-market hours following Tuesday's close, amid ongoing volatility within its one-month trading range.

19 de out. de 2026, 20:07 UTC

Pacific Biosciences announces a multi-year collaboration with Verily Health to integrate HiFi sequencing technology with Verily's AI platform for clinico-genomic datasets.

16 de out. de 2026, 23:06 UTC

Pacific Biosciences of California Inc is effectively unchanged in after-market trading, having retraced from earlier highs amid recent declines below its 20-day moving average.

15 de out. de 2026, 23:02 UTC

After-market hours, the ARK Genomic Revolution ETF (ARKG) is trading higher, supported by a Neutral rating for CRISPR Therapeutics from UBS and gains in key holdings.

14 de out. de 2026, 23:21 UTC

Pacific Biosciences shares declined in after-market trading, marking the fourth consecutive session of lower prices, reaching a recent low shortly before the latest timestamp.

13 de out. de 2026, 23:06 UTC

Pacific Biosciences of California Inc's shares were roughly flat in after-market trading, following three consecutive lower daily closes while remaining above the 20-day moving average.

12 de out. de 2026, 22:16 UTC

Pacific Biosciences of California Inc is trading roughly flat in after-market hours, with the stock positioned around the middle of its one-month range.

9 de out. de 2026, 20:07 UTC

UBS initiated coverage of Pacific Biosciences with a Neutral rating and a price target of $1.35, adjusting its Fair Value estimate to $2.40 per share.

8 de out. de 2026, 23:20 UTC

Pacific Biosciences shares declined significantly in after-market trading, reversing earlier gains and marking a notable drop compared to Thursday's close.

7 de out. de 2026, 23:06 UTC

Pacific Biosciences of California Inc declined during after-market hours on Wednesday, retracing significantly from its prior close despite strong recent performance.

6 de out. de 2026, 23:06 UTC

Pacific Biosciences of California Inc declined in after-market trading, moving lower since Tuesday's close, despite strong performance over the past month.